Lv42
606 积分 2025-04-02 加入
Case Report: Two cases of non-small cell lung cancer with coexistence of NTRK2 fusion and EGFR mutations
4小时前
已关闭
62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations
7天前
已完结
Dordaviprone (Modeyso) for Diffuse Midline Glioma
15天前
已关闭
Furmonertinib activity in NSCLC Harbouring EGFR L858R and ERBB2 S310F co-mutations: a case report with literature review
1个月前
已完结
Zorifertinib for EGFR-mutant Non-small Cell Lung Cancer after Leptomeningeal Metastasis on Double-Dose Third-generation EGFR-TKI: A Case Report and Literature Review
1个月前
已关闭
EP.12.41 FUTURE Trial:First-Stage Data of Initial Firmonertinib 160mg in EGFR+/PD-L1+ Locally Advanced or Metastatic NSCLC (Simon’s Two-Stage Design)
1个月前
已关闭
EP.12.38 Firmonertinib(160Mg) Combined With Chemotherapy as First-Line Treatment for Advanced NSCLC Patients With EGFR Mutations and Cns Metastases
1个月前
已关闭
P3.12.53 High-Dose Furmonertinib Plus Bevacizumab in EGFR-Mutant NSCLC With CNS Metastases After Resistance to Third-Generation EGFR-TKIs
1个月前
已关闭
EP.08.39 Adjuvant Therapy With Furmonertinib Significantly Reduces the Recurrence Rate in Lung Cancer Patients With Exon 20 Insertion Mutations
1个月前
已关闭
P3.12.38 Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations
1个月前
已关闭
护理专业学生参与安宁疗护实践体验质性研究的Meta整合
应用同轴微导管行多支血管栓塞治疗急性大咳血患者的护理
皖公网安备34019202002308
